WuXi XDC Cayman Inc. (HKG:2268)

Market Cap	38.52B
Revenue (ttm)	3.00B
Net Income (ttm)	638.84M
Shares Out	1.20B
EPS (ttm)	0.53
PE Ratio	60.82
Forward PE	33.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,692,516
Average Volume	5,429,095
Open	32.35
Previous Close	32.15
Day's Range	31.15 - 32.85
52-Week Range	14.08 - 38.10
Beta	n/a
RSI	50.69
Earnings Date	Mar 26, 2025

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China....

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2013
• Employees: 1,178
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2268

Financial Performance

In 2023, WuXi XDC Cayman's revenue was 2.12 billion, an increase of 114.44% compared to the previous year's 990.42 million. Earnings were 283.54 million, an increase of 82.07%.

Financial numbers in CNY